{
  "table_name": "PLATFORM.KNOWNDRUGSAGGREGATED",
  "table_fullname": "OPEN_TARGETS_PLATFORM_1.PLATFORM.KNOWNDRUGSAGGREGATED",
  "column_names": [
    "Präferenzname",
    "Status",
    "Wirkmechanismus",
    "URLs",
    "ZielId",
    "Vorfahren",
    "Handelsnamen",
    "KrankheitsId",
    "Synonyme",
    "Beschriftung",
    "ArzneimittelId",
    "Phase",
    "Zielname",
    "genehmigtesSymbol",
    "genehmigterName",
    "Arzneimitteltyp",
    "Zielklasse"
  ],
  "column_types": [
    "TEXT",
    "TEXT",
    "TEXT",
    "VARIANT",
    "TEXT",
    "VARIANT",
    "VARIANT",
    "TEXT",
    "VARIANT",
    "TEXT",
    "TEXT",
    "FLOAT",
    "TEXT",
    "TEXT",
    "TEXT",
    "TEXT",
    "VARIANT"
  ],
  "description": [
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null,
    null
  ],
  "sample_rows": [
    {
      "ArzneimittelId": "CHEMBL409",
      "ZielId": "ENSG00000169083",
      "KrankheitsId": "MONDO_0008315",
      "Phase": 2.0,
      "Status": "Recruiting",
      "URLs": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT04025372\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT04734730\"\n      }\n    },\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT03541928\"\n      }\n    }\n  ]\n}",
      "Vorfahren": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"EFO_0009555\"\n    },\n    {\n      \"element\": \"EFO_0007355\"\n    },\n    {\n      \"element\": \"MONDO_0024582\"\n    },\n    {\n      \"element\": \"MONDO_0002149\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"EFO_1000051\"\n    },\n    {\n      \"element\": \"EFO_0009602\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"MONDO_0021259\"\n    },\n    {\n      \"element\": \"MONDO_0004992\"\n    },\n    {\n      \"element\": \"EFO_0000512\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "Beschriftung": "prostate cancer",
      "genehmigtesSymbol": "AR",
      "genehmigterName": "androgen receptor",
      "Zielklasse": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "Präferenzname": "BICALUTAMIDE",
      "Handelsnamen": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "Synonyme": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "Arzneimitteltyp": "Small molecule",
      "Wirkmechanismus": "Androgen Receptor antagonist",
      "Zielname": "Androgen Receptor"
    },
    {
      "ArzneimittelId": "CHEMBL409",
      "ZielId": "ENSG00000169083",
      "KrankheitsId": "EFO_0000305",
      "Phase": 2.0,
      "Status": "Active, not recruiting",
      "URLs": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT03650894\"\n      }\n    }\n  ]\n}",
      "Vorfahren": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"MONDO_0021350\"\n    },\n    {\n      \"element\": \"MONDO_0000653\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"MONDO_0007254\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"MONDO_0004992\"\n    },\n    {\n      \"element\": \"EFO_0009483\"\n    },\n    {\n      \"element\": \"MONDO_0003274\"\n    },\n    {\n      \"element\": \"EFO_0003869\"\n    },\n    {\n      \"element\": \"EFO_0000313\"\n    },\n    {\n      \"element\": \"EFO_0010285\"\n    },\n    {\n      \"element\": \"EFO_0006858\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "Beschriftung": "breast carcinoma",
      "genehmigtesSymbol": "AR",
      "genehmigterName": "androgen receptor",
      "Zielklasse": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "Präferenzname": "BICALUTAMIDE",
      "Handelsnamen": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "Synonyme": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "Arzneimitteltyp": "Small molecule",
      "Wirkmechanismus": "Androgen Receptor antagonist",
      "Zielname": "Androgen Receptor"
    },
    {
      "ArzneimittelId": "CHEMBL409",
      "ZielId": "ENSG00000169083",
      "KrankheitsId": "MONDO_0007254",
      "Phase": 2.0,
      "Status": "Unknown status",
      "URLs": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT02910050\"\n      }\n    }\n  ]\n}",
      "Vorfahren": "{\n  \"list\": [\n    {\n      \"element\": \"EFO_0003869\"\n    },\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"MONDO_0021350\"\n    },\n    {\n      \"element\": \"MONDO_0000653\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"MONDO_0004992\"\n    },\n    {\n      \"element\": \"EFO_0010285\"\n    },\n    {\n      \"element\": \"EFO_0009483\"\n    },\n    {\n      \"element\": \"MONDO_0003274\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "Beschriftung": "breast cancer",
      "genehmigtesSymbol": "AR",
      "genehmigterName": "androgen receptor",
      "Zielklasse": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "Präferenzname": "BICALUTAMIDE",
      "Handelsnamen": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "Synonyme": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "Arzneimitteltyp": "Small molecule",
      "Wirkmechanismus": "Androgen Receptor antagonist",
      "Zielname": "Androgen Receptor"
    },
    {
      "ArzneimittelId": "CHEMBL409",
      "ZielId": "ENSG00000169083",
      "KrankheitsId": "EFO_0003869",
      "Phase": 2.0,
      "Status": "Recruiting",
      "URLs": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT06365788\"\n      }\n    }\n  ]\n}",
      "Vorfahren": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"MONDO_0021350\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"EFO_0010285\"\n    },\n    {\n      \"element\": \"EFO_0009483\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "Beschriftung": "breast neoplasm",
      "genehmigtesSymbol": "AR",
      "genehmigterName": "androgen receptor",
      "Zielklasse": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "Präferenzname": "BICALUTAMIDE",
      "Handelsnamen": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "Synonyme": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "Arzneimitteltyp": "Small molecule",
      "Wirkmechanismus": "Androgen Receptor antagonist",
      "Zielname": "Androgen Receptor"
    },
    {
      "ArzneimittelId": "CHEMBL409",
      "ZielId": "ENSG00000169083",
      "KrankheitsId": "EFO_0000673",
      "Phase": 3.0,
      "Status": "Terminated",
      "URLs": "{\n  \"list\": [\n    {\n      \"element\": {\n        \"niceName\": \"ClinicalTrials\",\n        \"url\": \"https://clinicaltrials.gov/study/NCT00514917\"\n      }\n    }\n  ]\n}",
      "Vorfahren": "{\n  \"list\": [\n    {\n      \"element\": \"OTAR_0000017\"\n    },\n    {\n      \"element\": \"MONDO_0024276\"\n    },\n    {\n      \"element\": \"EFO_0009555\"\n    },\n    {\n      \"element\": \"EFO_0007355\"\n    },\n    {\n      \"element\": \"MONDO_0024582\"\n    },\n    {\n      \"element\": \"MONDO_0002149\"\n    },\n    {\n      \"element\": \"MONDO_0023370\"\n    },\n    {\n      \"element\": \"EFO_1000051\"\n    },\n    {\n      \"element\": \"EFO_0009602\"\n    },\n    {\n      \"element\": \"MONDO_0045024\"\n    },\n    {\n      \"element\": \"MONDO_0021259\"\n    },\n    {\n      \"element\": \"MONDO_0004992\"\n    },\n    {\n      \"element\": \"MONDO_0008315\"\n    },\n    {\n      \"element\": \"EFO_0000512\"\n    },\n    {\n      \"element\": \"EFO_0000313\"\n    },\n    {\n      \"element\": \"EFO_0000228\"\n    },\n    {\n      \"element\": \"EFO_0001663\"\n    },\n    {\n      \"element\": \"EFO_0006858\"\n    },\n    {\n      \"element\": \"EFO_0000616\"\n    }\n  ]\n}",
      "Beschriftung": "prostate adenocarcinoma",
      "genehmigtesSymbol": "AR",
      "genehmigterName": "androgen receptor",
      "Zielklasse": "{\n  \"list\": [\n    {\n      \"element\": \"Transcription factor\"\n    },\n    {\n      \"element\": \"Unclassified protein\"\n    }\n  ]\n}",
      "Präferenzname": "BICALUTAMIDE",
      "Handelsnamen": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Calutide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"Cosudex\"\n    },\n    {\n      \"element\": \"Kalumid\"\n    }\n  ]\n}",
      "Synonyme": "{\n  \"list\": [\n    {\n      \"element\": \"Bicalutamide\"\n    },\n    {\n      \"element\": \"Casodex\"\n    },\n    {\n      \"element\": \"ICI 176,334\"\n    },\n    {\n      \"element\": \"ICI-176334\"\n    },\n    {\n      \"element\": \"ICI176,334-1\"\n    },\n    {\n      \"element\": \"NSC-759816\"\n    }\n  ]\n}",
      "Arzneimitteltyp": "Small molecule",
      "Wirkmechanismus": "Androgen Receptor antagonist",
      "Zielname": "Androgen Receptor"
    }
  ]
}